Publicaciones en colaboración con investigadores/as de Instituto de Salud Carlos III (12)

2023

  1. Clinical outcomes and antibody transfer in a cohort of infants with in utero or perinatal exposure to SARS-CoV-2 (Coronascope Study)

    European Journal of Pediatrics, Vol. 182, Núm. 10, pp. 4647-4654

  2. Corrigendum to “Dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: 48-week results of a non-randomized, pilot clinical trial (ART-PRO)” (EBioMedicine (2020) 55, (S2352396420301547), (10.1016/j.ebiom.2020.102779))

    eBioMedicine

  3. Superior neutralizing response after first versus second SARS-CoV-2 infection in fully vaccinated individuals

    Journal of Medical Virology, Vol. 95, Núm. 11

2022

  1. Cellular and humoral immune responses and breakthrough infections after three SARS-CoV-2 mRNA vaccine doses

    Frontiers in Immunology, Vol. 13

2021

  1. Detection of archived lamivudine-associated resistance mutations in virologically suppressed, lamivudine-experienced HIV-infected adults by different genotyping techniques (GEN-PRO study)

    Journal of Antimicrobial Chemotherapy, Vol. 76, Núm. 12, pp. 3263-3271

  2. Long-term efficacy of dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: Week 96 results of ART-PRO pilot study

    The Journal of antimicrobial chemotherapy, Vol. 76, Núm. 3, pp. 738-742

2019

  1. Lower expression of plasma-derived exosome miR-21 levels in HIV-1 elite controllers with decreasing CD4 T cell count

    Journal of Microbiology, Immunology and Infection, Vol. 52, Núm. 4, pp. 667-671

2016

  1. MicroRNA profile in CD8+ T-lymphocytes from HIV-infected individuals: Relationship with antiviral immune response and disease progression

    PLoS ONE, Vol. 11, Núm. 5

2015

  1. Use of cohort data to estimate national prevalence of transmitted drug resistance to antiretroviral drugs in Spain (2007-2012)

    Clinical Microbiology and Infection, Vol. 21, Núm. 1, pp. 105.e1-105.e5

2010

  1. Genotypic determination of HIV tropism - Clinical and methodological recommendations to guide the therapeutic use of CCR5 antagonists

    AIDS Reviews, Vol. 12, Núm. 3, pp. 135-148

2002

  1. Herramientas de laboratorio para individualizar el tratamiento: Resistencias y niveles de fármacos

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 20, Núm. SUPPL.2, pp. 35-47

2000

  1. Membrane raft microdomains mediate lateral assemblies required for HIV-1 infection

    EMBO Reports, Vol. 1, Núm. 2, pp. 190-196